Anticholinergic prescribing pattern changes of urogynecology providers in response to evidence of potential dementia risk
Menhaji K, Cardenas-Trowers OO, Chang OH, Hall EF, Ringel NE, Falk KN. Anticholinergic prescribing pattern changes of urogynecology providers in response to evidence of potential dementia risk. International Urogynecology Journal 2021, 32: 2819-2826. PMID: 33683426, DOI: 10.1007/s00192-021-04736-8.Peer-Reviewed Original ResearchConceptsAnticholinergic medicationsOveractive bladder syndrome treatmentMajority of respondentsDevelopment of dementiaRisk of dementiaPrior authorization processPrimary outcomePrescribing practicesResultsA totalSyndrome treatmentDementia riskPractice patternsInsurance barriersInsurance restrictionsMedicationsTreatment planWeb-based surveyImpact of insuranceDementiaRecent literatureAnticholinergicsAgonistsRiskDescriptive statisticsTreatmentRethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options.
Escobar CM, Falk KN, Mehta S, Hall EF, Menhaji K, Sappenfield EC, Brown OE, Ringel NE, Chang OH, Tellechea LM, Barnes HC, Jeney SES, Bennett AT, Cardenas-Trowers OO. Rethinking Second-Line Therapy for Overactive Bladder to Improve Patient Access to Treatment Options. Obstetrics And Gynecology 2021, 137: 454-460. PMID: 33543891, DOI: 10.1097/aog.0000000000004279.Commentaries, Editorials and LettersMeSH KeywordsAdrenergic beta-3 Receptor AgonistsAlgorithmsCholinergic AntagonistsDementiaHealth Services AccessibilityHumansUrinary Bladder, OveractiveConceptsOveractive bladderΒ3-adrenoceptor agonistHealth care inequalitiesOral medicationsFavorable side effect profileTreatment of OABAlternative oral treatmentSecond-line therapySide effect profileCare inequalitiesIdiopathic overactive bladderCognitive side effectsHealth care professionalsQuality of lifeProcedural therapiesOral treatmentEffect profileOAB medicationsTreatment algorithmTreatment optionsChronic conditionsCare professionalsSide effectsMedicationsBetter care"First, Do No Harm"-Trainees' Observation of Risk Reduction in the Treatment of Overactive Bladder.
Bennett AT, Ringel NE, Menhaji K, Brown OE, Hall EF, Cardenas-Trowers OO, Falk KN, Jeney SES, Barnes H, Escobar C, Tellechea LM, Sappenfield EC, Mehta S, Chang OH. "First, Do No Harm"-Trainees' Observation of Risk Reduction in the Treatment of Overactive Bladder. Urogynecology 2021, 27: 2-4. PMID: 33369964, DOI: 10.1097/spv.0000000000000978.Commentaries, Editorials and Letters